Gulf Pharmaceutical Industries P.S.C Past Earnings Performance
Past criteria checks 0/6
Gulf Pharmaceutical Industries P.S.C has been growing earnings at an average annual rate of 57.2%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 31% per year.
Key information
57.2%
Earnings growth rate
69.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 31.0% |
| Return on equity | -2.9% |
| Net Margin | -1.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified
Oct 16
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14Revenue & Expenses Breakdown
How Gulf Pharmaceutical Industries P.S.C makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,713 | -25 | 605 | 0 |
| 30 Jun 24 | 1,662 | -58 | 602 | 0 |
| 31 Mar 24 | 1,623 | -98 | 598 | 0 |
| 31 Dec 23 | 1,638 | -104 | 591 | 0 |
| 30 Sep 23 | 1,587 | -128 | 609 | 0 |
| 30 Jun 23 | 1,637 | -85 | 602 | 0 |
| 31 Mar 23 | 1,652 | -38 | 602 | 0 |
| 31 Dec 22 | 1,616 | -34 | 596 | 0 |
| 30 Sep 22 | 1,651 | -28 | 607 | 0 |
| 30 Jun 22 | 1,598 | 0 | 604 | 0 |
| 31 Mar 22 | 1,398 | 64 | 525 | 0 |
| 31 Dec 21 | 1,143 | 47 | 452 | 0 |
| 30 Sep 21 | 858 | -104 | 446 | 0 |
| 30 Jun 21 | 682 | -138 | 394 | 0 |
| 31 Mar 21 | 632 | -203 | 387 | 0 |
| 31 Dec 20 | 573 | -247 | 397 | 0 |
| 30 Sep 20 | 540 | -184 | 348 | 0 |
| 30 Jun 20 | 376 | -377 | 370 | 0 |
| 31 Mar 20 | 295 | -472 | 392 | 0 |
| 31 Dec 19 | 302 | -494 | 400 | 0 |
| 30 Sep 19 | 265 | -957 | 425 | 0 |
| 30 Jun 19 | 388 | -840 | 423 | 0 |
| 31 Mar 19 | 567 | -716 | 418 | 0 |
| 31 Dec 18 | 720 | -612 | 420 | 0 |
| 30 Sep 18 | 928 | -20 | 378 | 0 |
| 30 Jun 18 | 1,106 | 80 | 385 | 0 |
| 31 Mar 18 | 1,085 | 70 | 417 | 0 |
| 31 Dec 17 | 1,155 | 95 | 446 | 0 |
| 30 Sep 17 | 1,293 | 142 | 640 | 0 |
| 30 Jun 17 | 1,275 | 145 | 645 | 0 |
| 31 Mar 17 | 1,418 | 178 | 682 | 0 |
| 31 Dec 16 | 1,455 | 212 | 703 | 0 |
| 30 Sep 16 | 1,391 | 205 | 579 | 0 |
| 30 Jun 16 | 1,407 | 215 | 594 | 0 |
| 31 Mar 16 | 1,391 | 214 | 646 | 0 |
| 31 Dec 15 | 1,470 | 230 | 677 | 0 |
| 30 Sep 15 | 1,510 | 226 | 672 | 0 |
| 30 Jun 15 | 1,449 | 235 | 663 | 0 |
| 31 Mar 15 | 1,443 | 228 | 625 | 0 |
| 31 Dec 14 | 1,388 | 204 | 632 | 0 |
| 30 Sep 14 | 1,382 | 224 | 630 | 0 |
| 30 Jun 14 | 1,427 | 231 | 643 | 0 |
| 31 Mar 14 | 1,425 | 238 | 637 | 0 |
| 31 Dec 13 | 1,362 | 230 | 597 | 0 |
Quality Earnings: JULPHAR is currently unprofitable.
Growing Profit Margin: JULPHAR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JULPHAR is unprofitable, but has reduced losses over the past 5 years at a rate of 57.2% per year.
Accelerating Growth: Unable to compare JULPHAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JULPHAR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).
Return on Equity
High ROE: JULPHAR has a negative Return on Equity (-2.88%), as it is currently unprofitable.